ProKidney Corp. announced the promotion of Farah Ali, M.D., M.S., to Chief Medical Officer on November 18, 2026. Dr. Ali will lead the company's clinical programs as it advances the pivotal Phase 3 PROACT 1 study of its lead cell therapy candidate, rilparencel, toward potential regulatory filings.
ProKidney promoted Farah Ali, M.D., to Chief Medical Officer, an internal succession without financial figures, contract terms, trial data or guidance changes. It provides continuity as the Phase 3 PROACT 1 study of rilparencel advances toward potential regulatory filings, but contains no hard fact that materially changes the outlook for the stock.
- • Promotion of Farah Ali to Chief Medical Officer announced November 18, 2026
- • Company says it is preparing for anticipated clinical milestones and regulatory filings for the Phase 3 PROACT 1 study
- • No clinical data, financial figures or guidance accompany the appointment
- • Forward-looking statement section reiterates risks including possible need for additional financing, going-concern ability, and the FDA potentially requiring additional studies before approval